Exosomes are small vesicles produced by cells, from which they carry some very interesting properties. Stem-cells derived exosomes, in particular, are able to virtually replicate the regenerative properties of their parent cells.
Compared to stem cells, exosomes-based treatments offer simpler and more cost-efficient logistics, and greater ease of use for clinicians.
For patients, research has shown that exosomes have a more advantageous risk profile compared to stem cells : no donor rejection, no proliferation or differentiation risks.
The exosomes used in our treatments are produced with high-yield and scale-up compatible technologies. Compared to current-generation cell therapies, this allows for a 10x increase in production throughput in 10x less time.